Company profile

Sunshine Lake Pharma

Privately held: no public share price · China

Assets

(5 total)
5Total Assets
0Approved
2Phase 3 / Filed
3Phase 1–2 / Early
5Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Clifutinib Besylate
Phase 3
FLT3Small molecule
Acute Myeloid Leukemia
Mitizodone phosphate
Phase 3
Serotonin transporter/5-HT receptorSmall molecule
Major Depressive Disorder
HEC169096
Phase 2
RETSmall molecule
Non-Small Cell Lung Cancer
HEC53856
Phase 1
HIF prolyl hydroxylase domain (PHD1/2/3)Small molecule
Chronic Kidney Disease
Rongliflozin
Phase 1
SGLT2Small molecule
Type 2 Diabetes

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.